The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system.

COVID-19 coronavirus lockdown non-pharmaceutical interventions social distancing surveillance

Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
03 2021
Historique:
entrez: 19 3 2021
pubmed: 20 3 2021
medline: 25 3 2021
Statut: ppublish

Résumé

BackgroundA multi-tiered surveillance system based on influenza surveillance was adopted in the United Kingdom in the early stages of the coronavirus disease (COVID-19) epidemic to monitor different stages of the disease. Mandatory social and physical distancing measures (SPDM) were introduced on 23 March 2020 to attempt to limit transmission.AimTo describe the impact of SPDM on COVID-19 activity as detected through the different surveillance systems.MethodsData from national population surveys, web-based indicators, syndromic surveillance, sentinel swabbing, respiratory outbreaks, secondary care admissions and mortality indicators from the start of the epidemic to week 18 2020 were used to identify the timing of peaks in surveillance indicators relative to the introduction of SPDM. This timing was compared with median time from symptom onset to different stages of illness and levels of care or interactions with healthcare services.ResultsThe impact of SPDM was detected within 1 week through population surveys, web search indicators and sentinel swabbing reported by onset date. There were detectable impacts on syndromic surveillance indicators for difficulty breathing, influenza-like illness and COVID-19 coding at 2, 7 and 12 days respectively, hospitalisations and critical care admissions (both 12 days), laboratory positivity (14 days), deaths (17 days) and nursing home outbreaks (4 weeks).ConclusionThe impact of SPDM on COVID-19 activity was detectable within 1 week through community surveillance indicators, highlighting their importance in early detection of changes in activity. Community swabbing surveillance may be increasingly important as a specific indicator, should circulation of seasonal respiratory viruses increase.

Identifiants

pubmed: 33739255
doi: 10.2807/1560-7917.ES.2021.26.11.2001062
pmc: PMC7976385
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

JMIR Public Health Surveill. 2021 Feb 19;7(2):e24341
pubmed: 33605892
NPJ Digit Med. 2021 Feb 8;4(1):17
pubmed: 33558607
JMIR Public Health Surveill. 2020 Apr 2;6(2):e18606
pubmed: 32240095
Emerg Infect Dis. 2020 Aug;26(8):1740-1748
pubmed: 32343222
J Infect. 2020 May;80(5):578-606
pubmed: 32119884
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Clin Microbiol Infect. 2019 Oct;25(10):1266-1276
pubmed: 30790685
BMJ. 2020 Mar 25;368:m1182
pubmed: 32213507
J Travel Med. 2020 May 18;27(3):
pubmed: 32181488
Lancet Infect Dis. 2020 Jun;20(6):678-688
pubmed: 32213332
BMJ Open. 2020 Aug 16;10(8):e039652
pubmed: 32801208
Bull World Health Organ. 2021 Mar 1;99(3):178-189
pubmed: 33716340
Euro Surveill. 2020 Mar;25(9):
pubmed: 32156327
BMC Med. 2020 May 7;18(1):124
pubmed: 32375776
Lancet Public Health. 2020 May;5(5):e279-e288
pubmed: 32311320
Stud Health Technol Inform. 2018;247:161-165
pubmed: 29677943
Nature. 2020 Sep;585(7825):410-413
pubmed: 32365354

Auteurs

Jamie Lopez Bernal (JL)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Mary A Sinnathamby (MA)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Suzanne Elgohari (S)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Hongxin Zhao (H)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Chinelo Obi (C)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Laura Coughlan (L)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Vasileios Lampos (V)

Department of Computer Science, University College London, London, United Kingdom.

Ruth Simmons (R)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Elise Tessier (E)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Helen Campbell (H)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Suzanna McDonald (S)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Joanna Ellis (J)

Public Health England COVID-19 Virology Cell, London, United Kingdom.

Helen Hughes (H)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Gillian Smith (G)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Mark Joy (M)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), London, United Kingdom.

Manasa Tripathy (M)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), London, United Kingdom.

Rachel Byford (R)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), London, United Kingdom.

Filipa Ferreira (F)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), London, United Kingdom.

Simon de Lusignan (S)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), London, United Kingdom.

Maria Zambon (M)

Public Health England COVID-19 Virology Cell, London, United Kingdom.

Gavin Dabrera (G)

Public Health England COVID-19 Epidemiology Cell, London, United Kingdom.

Kevin Brown (K)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.
Public Health England COVID-19 Virology Cell, London, United Kingdom.

Vanessa Saliba (V)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Nick Andrews (N)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Gayatri Amirthalingam (G)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Sema Mandal (S)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Michael Edelstein (M)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Alex J Elliot (AJ)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Mary Ramsay (M)

Public Health England COVID-19 Surveillance Cell, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH